The Association of the British Pharmaceutical Industry (ABPI) has published a report benchmarking the UK’s cost-effectiveness threshold for health interventions against international standards. The findings suggest that the UK’s threshold, used by organisations like the National Institute for Health and Care Excellence (NICE) to determine the value of new medicines and treatments, is notably lower than that of other high-income nations.
According to the ABPI's analysis, the UK currently operates with a cost-effectiveness threshold estimated to be between £20,000 and £30,000 per Quality-Adjusted Life Year (QALY). A QALY is a measure combining both the quantity and quality of life, used to assess the value of medical interventions. This figure stands in stark contrast to the average threshold observed across comparable countries, which the report places in the range of £40,000 to £60,000 per QALY.
The report underscores that this discrepancy could have significant implications for the introduction and availability of new, innovative treatments within the National Health Service (NHS). A lower threshold means that medicines and technologies deemed cost-effective in other countries might not meet the UK's criteria, potentially delaying or even preventing their access for British patients. This comparison highlights a potential barrier to adopting cutting-edge therapies in the UK.
The methodology for determining these thresholds varies internationally, often reflecting different healthcare system structures, economic conditions, and societal values placed on health. However, the ABPI argues that the UK's current approach may be overly restrictive compared to its peers, potentially hindering the UK's ability to be a leader in healthcare innovation and patient outcomes.
This analysis comes at a time when the NHS faces increasing pressure to manage costs while simultaneously providing access to the latest medical advancements. The findings prompt a discussion about whether the current threshold adequately balances the need for financial sustainability with the imperative to offer patients the best possible care and access to life-changing treatments.